Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of GoodwillAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionDivestmentsExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesSales of Property, Plant and EquipmentShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Avanos Medical (AVNS) Other Working Capital Changes (2016 - 2025)

Avanos Medical (AVNS) has disclosed Other Working Capital Changes for 13 consecutive years, with -$9.7 million as the latest value for Q4 2025.

  • Quarterly Other Working Capital Changes rose 69.4% to -$9.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was -$10.4 million through Dec 2025, up 73.6% year-over-year, with the annual reading at -$10.4 million for FY2025, 73.6% up from the prior year.
  • Other Working Capital Changes hit -$9.7 million in Q4 2025 for Avanos Medical, down from $1.5 million in the prior quarter.
  • In the past five years, Other Working Capital Changes ranged from a high of $37.3 million in Q3 2021 to a low of -$46.7 million in Q2 2021.
  • Historically, Other Working Capital Changes has averaged -$3.5 million across 5 years, with a median of -$250000.0 in 2022.
  • Biggest five-year swings in Other Working Capital Changes: surged 1820.0% in 2021 and later tumbled 734.29% in 2023.
  • Year by year, Other Working Capital Changes stood at $17.2 million in 2021, then tumbled by 79.65% to $3.5 million in 2022, then tumbled by 734.29% to -$22.2 million in 2023, then crashed by 42.79% to -$31.7 million in 2024, then surged by 69.4% to -$9.7 million in 2025.
  • Business Quant data shows Other Working Capital Changes for AVNS at -$9.7 million in Q4 2025, $1.5 million in Q3 2025, and -$1.9 million in Q2 2025.